Previous 10 | Next 10 |
home / stock / phmmf / phmmf news
MADRID , Oct. 19, 2018 /PRNewswire/ -- Sylentis, PharmaMar Group (MCE: PHM), has announced today that it has reached its target of recruiting 300 patients for the Phase III trial "HELIX" [1] for the treatment of the signs and symptoms of dry eye disease. PharmaMar estimate tha...
MADRID , September 24, 2018 /PRNewswire/ -- The results are from Cohort B of the Phase I/II Study in patients with relapsed S mall C ell L ung C ancer (SCLC) . This study preceded the Phase III ATLANTIS s tudy with the same doses and a similar popul...
Akzo Nobel ( OTCQX:AKZOY +2.9% ) has acquired Xylazel, a 100% subsidiary of Pharma Mar ( OTCPK:PHMMF ), strengthening its business and becoming a leader in the decorative paints market in Spain. More news on: Akzo Nobel N.V. ADR, Pharma Mar SA, Akzo Nobel N.V., Merger & acquisition...
MADRID , Sept. 7, 2018 /PRNewswire/ -- Pharma Mar, S.A. (MCE: PHM) ("Pharma Mar" or the "Company") is announcing its intention to conduct a registered public offering of American Depositary Shares representing its shares in the United States. This was previously announced as one of t...
MADRID , September 6, 2018 /PRNewswire/ -- Th e results are from Cohort B of the P hase I /II Study in patients with s mall- c ell l ung c ancer, a study that predated the Phase II I ATLANTIS Study at the same dose level in a s imil...
MADRID , August 3, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for the treatment of small cell lung cancer (SCLC) S CLC is a very aggressive cancer, about 18% of all the lung cancer cases ...
MADRID , July 31, 2018 /PRNewswire/ -- ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital centers in 20 countries Top line data is expected to readout around the end of 2019 PharmaMar (MCE...
MADRID , July 27, 2018 /PRNewswire/ -- PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum Internatio...
MADRID , June 26, 2018 /PRNewswire/ -- PharmaMar regains all its rights for Zepsyre ® in Japan with immediate effec t and receives a payment of € 3,000, 000 from Chugai PharmaMar progresses in the clinical development of Zepsyre ® in...
MADRID , June 11, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Argentina , Bolivia , Brazi...
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Ebix Inc. (EBIXQ) is expected to report for Q1 2024 Amesite Inc. (AMST) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.68 for Q1 2025 Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A) (WDH) is expected to repo...
TDCX Inc. American Depositary Shares each representing one Class A (TDCX) is expected to report for Q1 2024 nCino Inc. (NCNO) is expected to report $0 for Q1 2025 SK Telecom Co. Ltd. (SKM) is expected to report for Q1 2024 Redeia Corporacion S.A. ADR (RDEIY) is expected to report for ...